The research and development of cell therapy products require an exceptional team of people with scientific and clinical expertise across a range of disciplines. We seek to forge collaborations with leading researchers and top medical centers to accelerate the development and rapid translation of our first-in-class product candidates into first-in-human clinical trials. We believe these collaborations will maximize our potential to successfully identify first-in-class product candidates, accelerate our product candidates’ clinical translation and investigation, and efficiently establish first-in-human proof-of-concept for our products.
Additionally, we seek to share our cell programming expertise with industry-leading partners for the development of first-in-class and best-in-class cell products. We believe we are uniquely positioned as the partner of choice to maximize the therapeutic potential of cell therapy products through ex vivo pharmacologic modulation. Additionally, we believe our proprietary iPSC product platform can be deployed in collaboration with strategic partners to create master iPSC lines and co-develop first-of-kind cell therapy products.